Epidemiology and microbiology of skin and soft tissue infections

Current Opinion in Infectious Diseases

Volumn 29, Issue 2, 2016, Pages 109-115

  Esposito, Silvano ^a   Noviello, Silvana ^a   Leone, Sebastiano ^a  

^a UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

Author keywords

Cause; Epidemiology; Methicillin resistant staphylococcus aureus; Skin and soft tissue infections

Indexed keywords

VANCOMYCIN;

BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL FEATURE; CLOSTRIDIUM; COMMUNITY; COMMUNITY ACQUIRED INFECTION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ECONOMIC ASPECT; EMERGENCY WARD; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HAEMOPHILUS INFLUENZAE; HEALTH CARE; HEALTH CARE COST; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS GROUP A; ACINETOBACTER; DERMATOMYCOSES; FUNGUS; ISOLATION AND PURIFICATION; PATHOLOGY; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; SURVIVAL ANALYSIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACINETOBACTER; DERMATOMYCOSES; FUNGI; HUMANS; LENGTH OF STAY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; SURVIVAL ANALYSIS; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84960127029     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000239     Document Type: Review

References (39)

1. Esposito S, Bassetti M, Borre' S, et al. Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. J Chemother 2011;23:251-262.
2. Esposito S, Leone S, Petta E, et al. Skin and soft tissue infections: classification and epidemiology. Infez Med 2009;17(Suppl 4):6-17.
3. Stevens DL, Bisno AL, Chambers HF, et al. Practice Guidelines for the diagnosis and management of skin and soft tissue infections: 2014 Update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59:147-159. Infectious Diseases Society of America guidelines on the diagnosis and management of SSTIs.
4. FDA guidelines for ABSSI drug development. http://www.fda.gov/down loads/Drugs/Guidances/ucm071185.pdf. [Accessed 15 October 2015]
5. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft tissue infections. Arch Intern Med 2008;168:1585-1591.
6. Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008;51:291-298.
7. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009;15:1516-1518.
8. Lautz TB, Raval MV, Barsness KA. Increasing national burden of hospitalizations for skin and soft tissue infections in children. J Pediatr Surg 2011;46:1935-1941.
9. Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U. S.population: a retrospective population-based study. BMC Infect Dis 2013;13:252.
10. Miller LG, Eisenberg DF, Liu H, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005-2010. BMC Infect Dis 2015;15:362. Large observational retrospective cohort study on ambulatory and hospitalized patients with SSTIs.
11. Esposito S, Leone S, Petta E, et al. Treatment options for skin and soft tissue infections caused by meticillin-resistant Staphylococcus aureus: oral vs.parenteral; home vs. hospital. Int J Antimicrob Agents 2009;34(Suppl 1):30-35.
12. Volz KA, Canham L, Kaplan E, et al. Identifying patients with cellulitis who are likely to require inpatient admission after a stay in an ED observation unit. Am J Emerg Med 2013;31:360-364.
13. Tiwari AK, Lal R. Study to evaluate the role of severity stratification of skin and soft tissue infections (SSTIs) in formulating treatment strategies and predicting poor prognostic factors. Int J Surg 2014;12:125-133. Prospective study on severity stratification of patients with SSTIs.
14. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996;334:240-245.
15. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S.aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-674.
16. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010;65(Suppl 3):35-44.
17. Ballus J, Lopez-Delgado JC, Sabater-Riera J, et al. Surgical site infection in critically ill patients with secondary and tertiary peritonitis: epidemiology, microbiology and influence in outcomes. BMC Infect Dis 2015;15:304. Prospective study on SSI in critically ill patients with secondary and tertiary peritonitis.
18. Micozzi A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 2000;31:705-711.
19. Bodey GP. Unusual presentations of infection in neutropenic patients. Int J Antimicrob Agents 2000;16:93-95.
20. Sarani B, Strong M, Pascual J, et al. Necrotizing fasciitis: current concepts and review of the literature. J Am Coll Surg 2009;208:279-288.
21. Brook I. Microbiology and management of soft tissue and muscle infections. Int J Surg 2008;6:328-338.
22. Esposito S, Leone S, Noviello S, et al. Foot infections in diabetes (DFIs) in the out-patient setting: an Italian multicentre observational survey. Diabet Med 2008;25:979-984.
23. Esposito S, Russo E, Noviello S, Leone S. Management of diabetic foot infections. Infez Med 2012;20(Suppl 1):28-34.
24. Ippolito G, Leone S, Lauria FN, et al. Methicillin-resistant Staphylococcus aureus: the superbug. Int J Infect Dis 2010;14(Suppl 4):7-11.
25. Stefani S, Chung DR, Lindsay JA, et al. Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents 2012;39:273-282.
26. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillinresistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005;45:311-320.
27. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007;51:423-428.
28. Talan DA, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011;53:144-149.
29. Jones RN, Nilius AM, Akinlade BK, et al. Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3381-3384.
30. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598.
31. Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multicenter matched outcomes study. PLoS One 2009;4:e8305.
32. Lee BY, Singh A, David MZ, et al. The economic burden of communityassociated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect 2013;19:528-536.
33. Esposito S, Noviello S, Leone S. Skin and soft tissue infections: current therapeutic options. Infez Med 2008;16:65-73.
34. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-2144.
35. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
36. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-3320.
37. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012;54:755-771.
38. Jacob JT, Diaz Granados CA. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis 2013;17:e93-e100.
39. Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA 2014;312:1552-1564.